2013’s Leading IP Developments Report – An Update

/ By / Others

A big thanks to our readers who’ve sent in suggestions for our upcoming SpicyIP report on 2013’s leading IP developments – namely, Shashank Mangal, Nehaa Chaudhari and two anonymous comments sent in. For readers who may have missed our earlier post, I’m referring to our request for input regarding our list of 2013’s biggest IP developments that we plan to write a report on. We’ve loosely defined ‘biggest’ as those with most jurisprudential value or those that have made a substantial […]

2013’s Leading IP Developments Report – An Update Read More »

SpicyIP Weekly Review (7th April to 13th April, 2014)

/ By / Others

SpicyIP Highlight of the Week! On 10th April, Thomson Reuters released a report titled ‘The Research and Innovation Performance of the G20’ highlighting the decisions taken in respect of scientific research and innovation activity by the G20 countries. It was heartening to discover that the report demonstrates how India has inched closer to bridging the scientific research and innovation gap with developed countries. Spadika has covered this here.   We, at SpicyIP, love blogging about the wackiest things doing the

SpicyIP Weekly Review (7th April to 13th April, 2014) Read More »

The Punjab Police to be Sued for Producing a Pirated CD in Court

/ By / Copyright

The Economic Times reports that director Sanjay Leela Bhansali is contemplating legal action against the Punjab Police for producing a pirated CD as evidence in a proceeding to quash an FIR registered against him. The article reports that at the time of the production of the CD in court, the film producers had given no rights for the release of any CD or DVD. The Punjab Police claim that they had obtained the CD from the person who had filed

The Punjab Police to be Sued for Producing a Pirated CD in Court Read More »

Novartis sues Biocon over anti-diabetes drug vildagliptin: Bitter pill?

/ By / Drug Regulation, Patent

A year after the Glivec saga and looks like Novartis is leaving no stone unturned to protect its blockbuster anti-diabetic vildagliptin. According to news reports, Novartis filed a suit seeking an injunction against Biocon Ltd. at the Delhi High Court for infringement of the vildagliptin product patent. During the hearing on March 28, 2014, the court recorded a statement according to which Biocon will not manufacture, sell or export Vildagliptin for commercial purposes till the next court hearing. Details of

Novartis sues Biocon over anti-diabetes drug vildagliptin: Bitter pill? Read More »

UNITAID on Trans-Pacific Partnership Agreement

/ By / Others, Uncategorized

UNITAID, which is hosted and administered by World Health Organisation, in its report titled “The Trans-Pacific Partnership Agreement: Implications for Access to Medicines and Public Health” (“Report”), voiced its opposition against Trans-Pacific Partnership Agreement (“TPPA”) which encapsulates TRIPS plus commitments. TPPA is positioned as a model agreement for future trade agreements including those involving developing countries. According to the Report, such agreements will delay generic market entry and competition which will in turn lead to increased prices of pharmaceuticals and

UNITAID on Trans-Pacific Partnership Agreement Read More »

Thomson Reuters’ Report on Research and Innovation Performance: India sees increase in research output; patent applications stable for the past decade

/ By / Innovation, Patent

Thomson Reuters has recently come out with a report titled ‘Research and Innovation Performance of the G20’ where scientific research and patent information has been mined to study the scale and impact of scientific research and innovation in the G20. The data was mined from Thomson Reuters’ proprietary databases including Web of Science and Derwent World Patent Index. Scientific Research: The Report casts light on India’s growing influence in the sphere of scientific research.  India, along with China, South Korea, Saudi

Thomson Reuters’ Report on Research and Innovation Performance: India sees increase in research output; patent applications stable for the past decade Read More »

SpicyIP Tidbit: Sun Pharmaceuticals-Ranbaxy deal

/ By / Others

Sun Pharmaceuticals, one of India’s largest drugmakers is acquiring competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo Co. Daiichi Sankyo, the majority shareholder in Ranbaxy will acquire a 9% stake in Sun Pharmaceuticals after the deal and also has an option to send a board member to Sun Pharmaceuticals. This deal, which comes when Ranbaxy is under some regulatory scrutiny in the USA (according to media reports), will catapult the combined entity to India’s largest pharma company and

SpicyIP Tidbit: Sun Pharmaceuticals-Ranbaxy deal Read More »

SpicyIP Weekly Review – 31st March to 6th April

/ By / Others

We started this week with Mathews reporting on the stay granted by the IPAB on the Chennai Patent Office’s order revoking Pfizer’s patent in the drug Detrol (read our original post here). The IPAB reasons that the balance of convenience is very much in favour of the petitioner for granting the relief of stay and that Ranbaxy had adequate time to appear and argue the matter and that there was no need to delay the matter any longer. Anubha then

SpicyIP Weekly Review – 31st March to 6th April Read More »

SpicyIP Tidbit: Astrazeneca sues Glenmark for infringement of anti-diabetes drug Saxagliptin

/ By / Drug Regulation, Patent

UK based Astrazeneca has sued Indian drugmaker Glenmark for patent infringement of its drug Saxagliptin, an anti-diabetes drug. The dispute arose due to Glenmark’s production and export of the drug Saxagliptin Monohydrate (API) in India, based on the Controller’s permission allowing Glenmark to manufacture the drug. Astrazeneca holds a patent in India until 2025 for the same drug. The Delhi High Court has granted a  status quo order on the matter, allowing Glenmark to continue manufacturing the drug. Glenmark has

SpicyIP Tidbit: Astrazeneca sues Glenmark for infringement of anti-diabetes drug Saxagliptin Read More »

At SpicyIP We Love IPR, Ab Ki Baar…

/ By / Copyright, Trademark

 Unless you have been hibernating or have a strong resolve to completely avoid social media, chances are that you have come across the latest viral ‘Ab Ki Baar, Modi Sarkar’ meme doing the rounds. Apart from attempting to make a few funny slogans myself, the ubiquity of the meme forced me to think about the IPR issues involved. In an earlier post, we have discussed the copyrightability of memes, where Devika concluded that a meme is usually protected from an

At SpicyIP We Love IPR, Ab Ki Baar… Read More »

Scroll to Top